CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...89101112131415161718...44724473»
  • ||||||||||  Review, Journal:  Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis. (Pubmed Central) -  Jul 24, 2025   
    Recent advancements in systemic therapies, such as sorafenib, lenvatinib, and immune checkpoint inhibitors (e.g., atezolizumab plus bevacizumab) have demonstrated improvements in overall survival and progression-free survival. These developments underscore the importance of a multidisciplinary and personalized approach to improve outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis.
  • ||||||||||  Review, Journal:  Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review. (Pubmed Central) -  Jul 24, 2025   
    Since 2020, immune checkpoint inhibitors have shown superior overall survival than sorafenib, leading to the adoption of combination therapies such as atezolizumab with bevacizumab and durvalumab with tremelimumab as first-line treatments...Second-line therapies now include regorafenib, cabozantinib, ramucirumab, nivolumab with ipilimumab, and pembrolizumab, each offering benefits for specific patient populations...Clinicians must be well-versed in these treatments and their potential side effects to provide optimal patient care. The emergence of combination therapies targeting complex biological pathways signifies a new paradigm in HCC treatment, emphasizing the importance of continuous education and vigilant monitoring to optimize patient outcomes.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, tiragolumab (RG6058) / Roche
    Journal, PD(L)-1 Biomarker, IO biomarker:  Dual targeting of CD155/TIGIT and PD-L1/PD-1 immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma. (Pubmed Central) -  Jul 24, 2025   
    Subsequent immunotherapeutic interventions with FDA-approved antibodies Tiragolumab (anti-TIGIT), Durvalumab (anti-PD-1), and their combination potentiated primary NK cell activation and killing of MB cell lines and PDX-derived MB organoids. These data propose a translatable and novel immunotherapeutic strategy for children diagnosed with subgroups Sonic Hedgehog and Group 3 MB.
  • ||||||||||  Journal:  Efficacy and safety of rituximab-based chemoimmunotherapy in adult patients with Burkitt lymphoma in Korea. (Pubmed Central) -  Jul 24, 2025   
    Therefore, high-intensity regimens including R-hyperCVAD/MC (Course A of rituximab, cyclophosphamide, doxorubicin, vincristine, and dexamethasone; Course B of rituximab, methotrexate, and cytarabine) have been commonly used; however, no optimal strategy has been established...Most of the patients were administered R-hyperCVAD/MC, while rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was administered to older patients or those with poor-performance-status to mitigate toxicity...Our study revealed that R-hyperCVAD/MC was effective but associated with high early mortality in older patients. Risk-adapted regimens and prognostic factors including age, B-symptoms, and ECOG-PS are crucial for optimizing treatment.
  • ||||||||||  Rituxan (rituximab) / Roche
    Review, Journal:  Dermatomyositis: A Narrative Review of Skin as a Window to Muscle and Malignancy. (Pubmed Central) -  Jul 24, 2025   
    First-line induction-concurrent chemoradiotherapy with sintilimab was identified as a cost-effectiveness treatment option for high-risk locoregionally advanced NPC. Dermatomyositis (DM) is a complex, systemic autoimmune disease characterized by hallmark cutaneous manifestations and inflammatory myopathy.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology
    Journal, IO biomarker:  The growing interests in Epstein-Barr virus: A bibliometric analysis of research trends, collaborations, and emerging hotspots. (Pubmed Central) -  Jul 24, 2025   
    On the basis of this comprehensive bibliometric analysis, it showed that the emerging hotspots included immunotherapy, biomarkers, viral reactivation, and vaccine development, with clinical trials evaluating immune-checkpoint inhibitors of toripalimab, mRNA-based therapeutic vaccines targeting LMP2 and EBNA1, and prophylactic strategies such as glycoproteins-based ferritin nanoparticles or mRNA vaccines, indicating a shift toward precision interventions...Advances enable targeted prophylactic/therapeutic strategies. The analysis highlights needs to decode virus-host interactions, optimize vaccines, and translate findings clinically, aiming to raise disease awareness, guide immunotherapies, and reduce global health burdens.
  • ||||||||||  ubenimex (DFP-14323) - Delta / Fly Pharma, tosedostat (CHR-2797) / SOBI
    Review, Journal:  Aminopeptidase N: a multifunctional and promising target in medicinal chemistry. (Pubmed Central) -  Jul 24, 2025   
    Some of them, such as bestatin or tosedostat, have already been tested as therapeutics with partial success. This article aims to bring an overview of multiple APN functions and implications for various diseases and their inhibitors which have already been prepared, and to suggest areas where the development of inhibitors may be promising in the future.
  • ||||||||||  Nplate (romiplostim) / Amgen
    Journal:  Safety and efficacy of romiplostim in children with acquired aplastic anemia who are na (Pubmed Central) -  Jul 24, 2025   
    This article aims to bring an overview of multiple APN functions and implications for various diseases and their inhibitors which have already been prepared, and to suggest areas where the development of inhibitors may be promising in the future. Not available.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Journal:  APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1-ALK Positive Anaplastic Large Cell Lymphoma. (Pubmed Central) -  Jul 24, 2025   
    Our results also reveal that disruption of the interaction weakens cell growth and augments the therapeutic efficacy of crizotinib and alectinib, ALK-TKIs, against ALK+ ALCL. Thus, high expression of APE1 indicates a faster growth of ALK+ ALCL; targeting this interaction may potentially achieve improved therapeutic outcomes, providing a reference for more precise treatment of ALK+ ALCL patients in clinical practice.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
    Review, Journal:  Rare presentation of immunoglobulin G4-related disease as tracheal stenosis: a case report and review of the literature. (Pubmed Central) -  Jul 24, 2025   
    In conclusion, IgG4-RD should be kept in mind in the differential diagnosis of patients presenting with clinical findings of tracheal stenosis. This study has shown that although most IgG4-RD patients with tracheal stenosis are controlled with glucocorticoids or surgical procedures, steroid-sparing agents may be needed to prevent relapses.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen, Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
    Review, Journal:  The next generation of immunotherapies for lung cancers. (Pubmed Central) -  Jul 24, 2025   
    This study has shown that although most IgG4-RD patients with tracheal stenosis are controlled with glucocorticoids or surgical procedures, steroid-sparing agents may be needed to prevent relapses. In 2024, regulatory approvals of the bispecific PD-1?
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Journal:  Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. (Pubmed Central) -  Jul 23, 2025   
    P3
    Treatment with tarlatamab led to longer overall survival than chemotherapy among patients with small-cell lung cancer whose disease had progressed during or after platinum-based chemotherapy. (Funded by Amgen; DeLLphi-304 ClinicalTrials.gov number, NCT05740566.).
  • ||||||||||  Review, Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications. (Pubmed Central) -  Jul 23, 2025   
    Despite these advances, immunotherapy faces substantial challenges including immune-related adverse events, acquired resistance through cancer immunoediting, and the need for biomarker-driven approaches to overcome tumor microenvironment barriers. This review discusses key clinical trials, therapeutic progress, and emerging modalities including CAR T-cell therapies and combination strategies, emphasizing the critical need to address resistance mechanisms and refine precision medicine approaches to fully realize immunotherapy's potential in GI malignancies.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies. (Pubmed Central) -  Jul 23, 2025   
    Since the advent of recombinant DNA technologies and leading up to the clinical approval of T cell engager blinatumomab, the modular design of therapeutic antibodies has enabled the fusion of antibody fragments with proteins of various functionalities...While many reviews have provided outstanding summaries of preclinical phase fbAbs and cataloged relevant clinical trials, to date, very few of the articles in searchable databases have comprehensively reviewed the details of clinical outcomes along with the underlying reasons or potential explanations for the success and failures of these fbAb drug products. To fill the gap, in this review, we seek to provide the readers with clinically driven insights, accompanied by translational and mechanistic studies, on the current landscape of fragment-based immune cell engager antibodies in treating cancer, infectious, and autoimmune diseases.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Neuromyelitis Optica Diagnosis in Two Elderly Patients with Systematic Lupus Erythematosus: A Case Series. (Pubmed Central) -  Jul 23, 2025   
    The coexistence of NMO with SLE is rare, but the occurrence of myelitis in patients with connective tissue diseases should raise the suspicion of NMO, especially in elderly women and several years after the diagnosis of SLE. Time to treatment is critical, as delays in treating NMO can result in cumulative and disabling damage.